Alcohol Addiction - Pipeline Review, H2 2017

Published: Jul, 2017 | Pages: 132 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H2 2017, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 10, 3, 1, 19 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Alcohol Addiction - Overview
Alcohol Addiction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Alcohol Addiction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Alcohol Addiction - Companies Involved in Therapeutics Development
AbbVie Inc
Addex Therapeutics Ltd
Adial Pharmaceuticals LLC
Arbor Pharmaceuticals LLC
AstraZeneca Plc
BioCorRx Inc
Bionex Pharmaceuticals LLC
Cerecor Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Curemark LLC
Eli Lilly and Company
Ethypharm SA
H. Lundbeck A/S
Heptares Therapeutics Ltd
Indivior Plc
Kinnov Therapeutics SAS
Kyorin Pharmaceutical Co Ltd
Lohocla Research Corp
Montisera Ltd
Omeros Corp
Opiant Pharmaceuticals Inc
Pfizer Inc
Silence Therapeutics Plc
SK Biopharmaceuticals Co Ltd
Tonix Pharmaceuticals Holding Corp
Zynerba Pharmaceuticals Inc
Alcohol Addiction - Drug Profiles
(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(disulfiram + selegiline) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
18-MC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-705253 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABT-436 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71441 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
amitifadine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANS-6637 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
arbaclofen placarbil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-1001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AT-200 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baclofen - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carisbamate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CERC-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CM-1212 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
D-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gabapentin enacarbil ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GET-73 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibudilast - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDTic - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nalmefene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
naltrexone hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
odelepran hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotides for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OMS-527 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ondansetron hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPNT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SKL-10406 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VMD-2202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alcohol Addiction - Dormant Projects
Alcohol Addiction - Discontinued Products
Alcohol Addiction - Product Development Milestones
Featured News & Press Releases
May 04, 2017: Addex ADX71441 Preclinical Results for Treatment of Alcohol Use Disorder Published in Journal of Psychopharmacology
Feb 28, 2017: Opiant Pharmaceuticals Receives FDA Feedback Supporting Clinical Development of OPNT002 for the Treatment of Alcohol Use Disorder
Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence
Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA
Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product
Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients
Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology
Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder
Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health
Jul 14, 2016: BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant
Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana
Jan 14, 2016: BioCorRx Announces New Agreements With Wellness Centers in Slidell, LA, Memphis and Nashville, TN, and Philadelphia, PA
Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Alcohol Addiction, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Alcohol Addiction - Pipeline by AbbVie Inc, H2 2017
Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H2 2017
Alcohol Addiction - Pipeline by Adial Pharmaceuticals LLC, H2 2017
Alcohol Addiction - Pipeline by Arbor Pharmaceuticals LLC, H2 2017
Alcohol Addiction - Pipeline by AstraZeneca Plc, H2 2017
Alcohol Addiction - Pipeline by BioCorRx Inc, H2 2017
Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H2 2017
Alcohol Addiction - Pipeline by Cerecor Inc, H2 2017
Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, H2 2017
Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, H2 2017
Alcohol Addiction - Pipeline by Curemark LLC, H2 2017
Alcohol Addiction - Pipeline by Eli Lilly and Company, H2 2017
Alcohol Addiction - Pipeline by Ethypharm SA, H2 2017
Alcohol Addiction - Pipeline by H. Lundbeck A/S, H2 2017
Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd, H2 2017
Alcohol Addiction - Pipeline by Indivior Plc, H2 2017
Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H2 2017
Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Alcohol Addiction - Pipeline by Lohocla Research Corp, H2 2017
Alcohol Addiction - Pipeline by Montisera Ltd, H2 2017
Alcohol Addiction - Pipeline by Omeros Corp, H2 2017
Alcohol Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
Alcohol Addiction - Pipeline by Pfizer Inc, H2 2017
Alcohol Addiction - Pipeline by Silence Therapeutics Plc, H2 2017
Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2017
Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H2 2017
Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2017
Alcohol Addiction - Dormant Projects, H2 2017
Alcohol Addiction - Dormant Projects, H2 2017 (Contd..1), H2 2017
Alcohol Addiction - Dormant Projects, H2 2017 (Contd..2), H2 2017
Alcohol Addiction - Discontinued Products, H2 2017